BIOVF
Price
$28.97
Change
-$0.82 (-2.75%)
Updated
Aug 12 closing price
Capitalization
9.82B
BIOYF
Price
$8.20
Change
-$0.05 (-0.61%)
Updated
Aug 14 closing price
Capitalization
93.29M
Interact to see
Advertisement

BIOVF vs BIOYF

Header iconBIOVF vs BIOYF Comparison
Open Charts BIOVF vs BIOYFBanner chart's image
Swedish Orphan Biovitrum AB
Price$28.97
Change-$0.82 (-2.75%)
Volume$500
Capitalization9.82B
BioSyent
Price$8.20
Change-$0.05 (-0.61%)
Volume$1.9K
Capitalization93.29M
BIOVF vs BIOYF Comparison Chart in %
Loading...
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIOYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIOVF vs. BIOYF commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOVF is a Hold and BIOYF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (BIOVF: $28.97 vs. BIOYF: $8.20)
Brand notoriety: BIOVF and BIOYF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOVF: 180% vs. BIOYF: 737%
Market capitalization -- BIOVF: $9.82B vs. BIOYF: $93.29M
BIOVF [@Pharmaceuticals: Generic] is valued at $9.82B. BIOYF’s [@Pharmaceuticals: Generic] market capitalization is $93.29M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOVF’s FA Score shows that 0 FA rating(s) are green whileBIOYF’s FA Score has 1 green FA rating(s).

  • BIOVF’s FA Score: 0 green, 5 red.
  • BIOYF’s FA Score: 1 green, 4 red.
According to our system of comparison, BIOYF is a better buy in the long-term than BIOVF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOVF’s TA Score shows that 3 TA indicator(s) are bullish while BIOYF’s TA Score has 3 bullish TA indicator(s).

  • BIOVF’s TA Score: 3 bullish, 3 bearish.
  • BIOYF’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, BIOVF is a better buy in the short-term than BIOYF.

Price Growth

BIOVF (@Pharmaceuticals: Generic) experienced а -2.75% price change this week, while BIOYF (@Pharmaceuticals: Generic) price change was -1.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOVF($9.82B) has a higher market cap than BIOYF($93.3M). BIOVF has higher P/E ratio than BIOYF: BIOVF (21.90) vs BIOYF (16.88). BIOYF YTD gains are higher at: 7.242 vs. BIOVF (4.736). BIOVF has higher annual earnings (EBITDA): 9.77B vs. BIOYF (11.3M). BIOVF has more cash in the bank: 1.06B vs. BIOYF (17.4M). BIOYF has less debt than BIOVF: BIOYF (990K) vs BIOVF (12.8B). BIOVF has higher revenues than BIOYF: BIOVF (27B) vs BIOYF (38.3M).
BIOVFBIOYFBIOVF / BIOYF
Capitalization9.82B93.3M10,528%
EBITDA9.77B11.3M86,478%
Gain YTD4.7367.24265%
P/E Ratio21.9016.88130%
Revenue27B38.3M70,496%
Total Cash1.06B17.4M6,080%
Total Debt12.8B990K1,292,929%
FUNDAMENTALS RATINGS
BIOVF vs BIOYF: Fundamental Ratings
BIOVF
BIOYF
OUTLOOK RATING
1..100
9253
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
6336
SMR RATING
1..100
6442
PRICE GROWTH RATING
1..100
5854
P/E GROWTH RATING
1..100
9357
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOYF's Valuation (26) in the null industry is somewhat better than the same rating for BIOVF (81). This means that BIOYF’s stock grew somewhat faster than BIOVF’s over the last 12 months.

BIOYF's Profit vs Risk Rating (36) in the null industry is in the same range as BIOVF (63). This means that BIOYF’s stock grew similarly to BIOVF’s over the last 12 months.

BIOYF's SMR Rating (42) in the null industry is in the same range as BIOVF (64). This means that BIOYF’s stock grew similarly to BIOVF’s over the last 12 months.

BIOYF's Price Growth Rating (54) in the null industry is in the same range as BIOVF (58). This means that BIOYF’s stock grew similarly to BIOVF’s over the last 12 months.

BIOYF's P/E Growth Rating (57) in the null industry is somewhat better than the same rating for BIOVF (93). This means that BIOYF’s stock grew somewhat faster than BIOVF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOVFBIOYF
RSI
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
48%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
47%
Bearish Trend 2 days ago
46%
Momentum
ODDS (%)
Bearish Trend 2 days ago
48%
Bullish Trend 2 days ago
44%
MACD
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
38%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
42%
Bearish Trend 2 days ago
39%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
42%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
57%
Bullish Trend 2 days ago
53%
Aroon
ODDS (%)
Bullish Trend 2 days ago
47%
Bearish Trend 2 days ago
44%
View a ticker or compare two or three
Interact to see
Advertisement
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIOYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JADE56.060.80
+1.44%
JPMorgan Active Developing Mkts Eq ETF
JPXN84.881.18
+1.41%
iShares JPX-Nikkei 400 ETF
HDEF30.010.19
+0.64%
Xtrackers MSCI EAFE High Div Yld Eq ETF
HTAB18.600.02
+0.11%
Hartford Schroders Tax-Aware Bond ETF
APRZ36.91N/A
N/A
TrueShares Structured Outcome April ETF

BIOYF and

Correlation & Price change

A.I.dvisor tells us that BIOYF and BUDZ have been poorly correlated (+6% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOYF and BUDZ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOYF
1D Price
Change %
BIOYF100%
-0.05%
BUDZ - BIOYF
6%
Poorly correlated
-13.11%
AVCNF - BIOYF
1%
Poorly correlated
-2.28%
APNHY - BIOYF
0%
Poorly correlated
N/A
BSPK - BIOYF
0%
Poorly correlated
N/A
BIOVF - BIOYF
0%
Poorly correlated
N/A
More